CervoMed

CervoMed Inc. is a clinical-stage biotechnology company developing treatments for age-related neurologic disorders, and is the successor to EIP Pharma Inc., which launched in 2014 and merged with Diffusion Pharmaceuticals in a transaction completed in late 2023 that created the present Nasdaq-listed entity. The company's sole clinical asset is neflamapimod, an orally administered, brain-penetrant small-molecule inhibitor of the p38 MAP kinase alpha isoform that targets neuroinflammation-induced synaptic dysfunction rather than amyloid or tau pathology directly. Neflamapimod is in mid-stage development across three distinct indications: dementia with Lewy bodies, where the Phase 2b RewinD-LB study is the lead program; nonfluent variant primary progressive aphasia, a frontotemporal dementia subtype associated with tau pathology; and recovery after ischemic stroke. The company holds an Innovation Passport for neflamapimod in dementia with Lewy bodies under the UK's Innovative Licensing and Access Pathway and receives grant support from the National Institute on Aging for part of the Lewy body dementia program, but has no approved products and no product revenue.